A 62-Year-Old Woman with HR+ HER2-low Metastatic Breast Cancer and Lung, Liver, and Bone Metastases and Using Biomarker Testing to Guide Treatment Selection
Virginia Kaklamani, MD, DSc, presents a case of metastatic breast cancer, initially responsive to first-line aromatase and CDK4/6 inhibitors, that progressed after 32 months. She explores using biomarker testing to identify ESR1 and other actionable mutations potentially causing endocrine resistance, guiding the transition to second-line therapy.
EP: 1.A 62-Year-Old Woman with HR+ HER2-low Metastatic Breast Cancer and Lung, Liver, and Bone Metastases and Using Biomarker Testing to Guide Treatment Selection
EP: 2.EMERALD: Underscoring Key Elacestrant Data + Subgroup Analyses for Informed Therapy Selection
EP: 3.Managing Toxicities and Adverse Reactions in HR+/Her2-Low mBC Therapies
Peers Discuss Sacituzumab Govitecan in HR+ mBC Post Endocrine Therapy
July 24th 2024During a Case-Based Roundtable® event, Tiffany A. Traina, MD, surveyed participants on treatment for a patient who had progressed following endocrine therapy for metastatic breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
